Table 2. Baseline characteristics of enrolled patients by treatment groups. A-lisinopril and/or lisinopril +hydrochlorothiazide; B-losartan and/or losartan + hydrochlorothiazide;
| Treatment groups | ||||||||
|---|---|---|---|---|---|---|---|---|
| A N=237 |
B N=78 |
C N=180 |
D N=81 |
E N=29 |
F N=60 |
P | ||
| Age (mean ± SD) | 61.01±9.6 | 57.01±11.8* | 61.28±9.2 | 60.01±8.4 | 60.97±9.8 | 62.02±7.7 | 0.016 | |
| Gender M/F (%) | 38.1/61.9 | 38.5/61.5 | 41.7/58.3 | 38.3/61.7 | 48.3/51.7 | 38.3/61.7 | 0.9 | |
| BMI (kg/m2) | 29.6±15.3 | 28.6±5.6 | 30.3±11.3 | 28.7±4.1 | 28.1±3.5 | 30.0±4.7 | 0.8 | |
| Waist circumference (cm) | 95.3±15.3 | 95.7±18.9 | 98.6±13.9 | 95.0±15.4 | 90.2±18.2 | 100.0±13.6 | 0.07 | |
| Physical activity (%) | 60.2 | 52.6 | 52.0 | 55.8 | 48.1 | 65.5 | 0.32 | |
| Smoking (%) | Non-smoker | 54.7 | 42.1 | 54.2 | 50.6 | 44.8 | 60.0 | 0.54 |
| Ex- smoker | 22.5 | 25.0 | 20.1 | 17.3 | 24.1 | 20.0 | ||
| Smoker | 22.8 | 32.9 | 25.7 | 32.1 | 31.1 | 20.0 | ||
| Alcohol consumption (%) | 6.96 | 14.5 | 10.6 | 15.2 | 14.8 | 8.5 | 0.22 | |
| Diabetes mellitus (%) | 19.6 | 27.3 | 28.9 | 20.3 | 22.2 | 32.1 | 0.18 | |
| Antidiabetic drugs (%) | 14.9 | 18.4 | 24.3 | 19.0 | 17.2 | 23.7 | 0.11 | |
| Lipid-lowering drugs (%) | 56.4 | 51.9 | 59.0 | 64.6 | 75.9** | 75.0** | 0.025 | |
| Cholesterol (mmol/L) | 5.8±1.2 | 6.2±4.5 | 5.7±1.2 | 5.8±1.2 | 6.1±1.2 | 6.3±1.3 | 0.23 | |
| Triglycerides (mmol/L) | 2.2±1.3 | 2.2±0.9 | 2.3±1.3 | 2.2±1.1 | 2.4±1.1 | 2.5±1.2 | 0.62 | |
| Blood glucose (mmol/L) | 6.0±1.8 | 5.9±1.2 | 6.2±1.7 | 6.9±1.3 | 5.9±1.3 | 6.4±1.5 | 0.23 | |